^
Association details:
Biomarker:MYC expression + MYC rearrangement
Cancer:Lymphoma
Drug Class:Aurora kinase inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

RECURRENCE OF THE 8Q24 REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM AND ITS ASSOCIATION WITH IMMUNOBLASTOID CYTOMORPHOLOGY, MYC EXPRESSION, AND DRUG RESPONSE

Published date:
05/17/2018
Excerpt:
Specimens and clinical information from 154 patients diagnosed with BPDCN...Forty-one (38%) MYC+BPDCN (positive for rearrangement and expression) and 59 (54%) MYC-BPDCN (both negative) cases were identified….Inhibitors for bromodomain and extraterminal protein (BETis) and aurora kinases (AKis) inhibited CAL-1 growth more effectively than that of PMDC05.